Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jun 24;9(6):e04298.
doi: 10.1002/ccr3.4298. eCollection 2021 Jun.

Successful management of therapy-related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil

Soichiro Nakako  1 , Teruhito Takakuwa  1 , Hirona Ichimura  1 , Hiroshi Okamura  1 , Satoru Nanno  1 , Mitsutaka Nishimoto  1 , Yasuhiro Nakashima  1 , Hideo Koh  1 , Masayuki Hino  1 , Hirohisa Nakamae  1
Affiliations
Case Reports

Successful management of therapy-related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil

Soichiro Nakako et al. Clin Case Rep. .

Abstract

A 55-year-old man was diagnosed with therapy-related chronic myelomonocytic leukemia (t-CMML) after exposure to tegafur/gimeracil/oteracil. Although he was refractory to hydroxyurea and low-dose cytarabine, combination therapy with cytarabine, aclarubicin and azacitidine (CA-AZA) provided good disease control, and he underwent allogeneic stem cell transplantation. This report has two key massages. First, tegafur/gimeracil/oteracil may have a potential risk of developing t-CMML. Second, CA-AZA therapy may be considered as a therapeutic option for patients with t-CMML.

Keywords: CA‐AZA; azacitidine; chronic myelomonocytic leukemia; tegafur; therapy related.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

FIGURE 1
FIGURE 1
Clinical course after treatment. CA‐AZA: cytarabine, aclarubicin, and azacitidine therapy; HU: hydroxyurea; LD‐AraC: low‐dose cytarabine; WBC: white blood cell count
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95(1):97‐115. - PubMed
    1. Patnaik MM, Vallapureddy R, Yalniz FF, et al. Therapy related‐chronic myelomonocytic leukemia (CMML): molecular, cytogenetic, and clinical distinctions from de novo CMML. Am J Hematol. 2018;93(1):65‐73. - PubMed
    1. Takahashi K, Pemmaraju N, Strati P, et al. Clinical characteristics and outcomes of therapy‐related chronic myelomonocytic leukemia. Blood. 2013;122(16):pp. 2807‐2811; quiz 2920. - PMC - PubMed
    1. Savona MR, Malcovati L, Komrokji R, et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 2015;125(12):1857‐1865. - PMC - PubMed
    1. Abe M, Tanaka Y, Shinohara M, Kosaka M, Matsumoto T. Myelodysplastic syndrome/acute myelogenous leukaemia related to adjuvant chemotherapy with oral pyrimidine anti‐metabolites. Br J Haematol. 2000;111(2):712‐713. - PubMed

Publication types

LinkOut - more resources